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Abstract
Ehlers-Danlos syndrome type IV, the vascular type of Ehlers-Danlos syndromes (EDS), is an
inherited connective tissue disorder defined by characteristic facial features (acrogeria) in most
patients, translucent skin with highly visible subcutaneous vessels on the trunk and lower back, easy
bruising, and severe arterial, digestive and uterine complications, which are rarely, if at all, observed
in the other forms of EDS. The estimated prevalence for all EDS varies between 1/10,000 and 1/
25,000, EDS type IV representing approximately 5 to 10% of cases. The vascular complications may
affect all anatomical areas, with a tendency toward arteries of large and medium diameter.
Dissections of the vertebral arteries and the carotids in their extra- and intra-cranial segments
(carotid-cavernous fistulae) are typical. There is a high risk of recurrent colonic perforations.
Pregnancy increases the likelihood of a uterine or vascular rupture. EDS type IV is inherited as an
autosomal dominant trait that is caused by mutations in the COL3A1 gene coding for type III
procollagen. Diagnosis is based on clinical signs, non-invasive imaging, and the identification of a
mutation of the COL3A1 gene. In childhood, coagulation disorders and Silverman's syndrome are
the main differential diagnoses; in adulthood, the differential diagnosis includes other Ehlers-Danlos
syndromes, Marfan syndrome and Loeys-Dietz syndrome. Prenatal diagnosis can be considered in
families where the mutation is known. Choriocentesis or amniocentesis, however, may entail risk
for the pregnant woman. In the absence of specific treatment for EDS type IV, medical intervention
should be focused on symptomatic treatment and prophylactic measures. Arterial, digestive or
uterine complications require immediate hospitalisation, observation in an intensive care unit.
Invasive imaging techniques are contraindicated. Conservative approach is usually recommended
when caring for a vascular complication in a patient suffering from EDS type IV. Surgery may,
however, be required urgently to treat potentially fatal complications.
Disease name and synonyms
Ehlers-Danlos syndrome type IV
Sack-Barabas syndrome
Vascular Ehlers-Danlos syndrome
Vascular type of Ehlers-Danlos syndromes (EDS)
Definition
Ehlers-Danlos syndrome type IV, also known as the vascu-
lar type of Ehlers-Danlos syndromes (EDS), is an inher-
ited disorder of connective tissue characterised by severe
arterial and digestive complications which are rarely, if at
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all, observed in the other forms EDS [1,2]. Patients with
EDS type IV, most of whom display characteristic facial
features and premature ageing of limb extremities (acrog-
eria), are predisposed to vascular and digestive ruptures,
as well as perforations of the gravid uterus. Arterial rup-
tures account for the majority of deaths, whilst digestive
perforations, occurring mainly on the sigmoid colon, are
less often fatal. These complications, rare in childhood,
affect 25% of patients before the age of 20, and 80% by
the age of 40 [1]. The median age of death is estimated to
be 50 years. Due to different clinical symptoms, natural
history and prognosis, EDS type IV should be assessed
separately within the group of EDS.
Epidemiology
The Ehlers-Danlos syndromes are a group of hereditary
disorders of connective tissue, whose prevalence is esti-
mated between 1/10,000 and 1/25,000, with no ethnic
predisposition. The Villefranche classification identifies
six clinical types (Table 1) [3], among which the vascular
EDS (OMIM #130050) accounts for about 5 to10% of
cases [4].
Clinical presentation
Clinical diagnosis of vascular Ehlers-Danlos syndrome is
based on four criteria: a characteristic facial aspect (acrog-
eria) in most patients, thin and translucent skin with
highly visible subcutaneous vessels, ecchymoses and hae-
matomas, and arterial, digestive and obstetrical complica-
tions.
A. Facial dysmorphy
When present, acrogeria is defined by characteristic facial
features such an emaciated face with prominent cheek-
bones and sunken cheeks. The eyes appear sunken or
bulging, often with colouring around them and thin tel-
angiectasia on the eyelids [5]. The nose is pinched and
thin, as are the lips, particularly the upper lip whose edges
are undefined [5]. A non-acrogeric form of the syndrome
may also exist, whose clinical diagnosis is more difficult as
several distinguishing features are not present [6].
B. Skin symptoms
In vascular EDS, the skin is abnormally thin and pale. It is
smooth, soft and velvety. The veins under the skin are dis-
tinctly visible as the skin is translucent on the thorax, the
shoulders and, sometimes, the abdomen. The skin on the
extremities appears prematurely aged, hence the term
acrogeria, and the subcutaneous veins are highly visible.
We have recently shown that anteflexion of the trunk dur-
ing clinical examination reveals highly visible subcutane-
ous vessels on the lower back. In our experience, this sign
has proved highly valuable in establishing the clinical
diagnosis [Germain DP, unpublished data].
However, there is no hyperelasticity of the skin in EDS
type IV, in contrast to classical EDS (types I and II) and
hypermobile EDS (type III) [7]. Fragility of the skin may
be observed, though less often than in classical EDS. This
leads to wounds with an abnormally long scarring proc-
ess. Secondary enlargement of scars and deposits of resid-
ual haemosiderin are typical.
C. Ecchymoses and haematomas
Ecchymoses and haematomas are common [6] and exten-
sive bruising (Figure 1) is one of the major diagnostic cri-
teria in the Villefranche nosology of Ehlers-Danlos
syndromes [3].
D. Complications
Patients suffering from vascular EDS are prone to arterial,
digestive and obstetrical complications.
Table 1: Classification of Ehlers-Danlos syndromes
Type Former nosology OMIM # Inheritance Gene and locus References
Classical type Type I 130000 ADa COL5A1, 9q34
COL5A2, 17q21
Other?
[59, 60]
Classical type Type II 130010 AD COL5A1, 9q34
COL5A217q21
Other?
[59, 60]
Ehlers-Danlos like syndrome with Tenascin X deficiency 606408 ARb TNXB, 6p21.3 [61] [62]
Hypermobility type Type III 130020 AD TNXB, 6p21.3
Other?
[63]
Vascular type Type VIA
Type VIB
225400 AR PLOD, 1p36
?
[64]
Arthrochalasia type Types VIIA and VIIB 130060 AD COL1A1, 17q21
COL1A2, 7q22
[65] [66]
Dermatosparaxis type Type VIIC 225410 AR ADAMTS2, 5q23 [67]
Progeroid type 130070 AD XGPT1, 5q35 [68]
Periodontitis type Type VIII 130080 AD ?, 12p13 [69]
Ehlers-Danlos variant with periventricular heterotopia 300537 XLc FLNA, Xq28 [70]
aAD: Autosomal dominant
bAR: Autosomal resessive
cXL: X-linkedOrphanet Journal of Rare Diseases 2007, 2:32 http://www.OJRD.com/content/2/1/32
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1) Vascular complications
The exact nature of the vascular lesions is disputed in the
literature, as most of these correspond to arterial dissec-
tions or tears caused by the deterioration of congenitally
thin and fragile tissue, leading to haematomas, false aneu-
rysms or intracavitary bleeding. Most of the aneurysms
recorded in the literature are probably 'false aneurysms',
even though a percentage of patients display real fusiform
aneurysms [8]. Arterial ruptures or dissections are respon-
sible for the majority of deaths as they are unpredictable
[9] and because the fragility of arterial walls often makes
the surgical repair difficult [10-13].
All anatomical areas can be affected, with a tendency
toward arteries of large and medium calibre [14]. The dis-
ease frequently involves the proximal branches of the aor-
tic arch, the descending thoracic aorta and the abdominal
aorta. The distal branches of the aorta, especially the renal,
mesenteric, iliac and femoral arteries, are also particularly
affected [10,15-17].
Dissections of the vertebral arteries and the carotids in
their extra- and intra-cranial segments have been widely
documented and are a typical complication of the syn-
drome (Figures 2, 3) [18-20]. Carotid-cavernous fistulae
(CCF) are another typical complication of EDS type IV
[21,22] due to reduced content of collagen III in the arte-
rial walls. CCF clinical diagnosis is based on the existence
of tinnitus, thrill, headaches and pulsating exophthalmos
[16,18,19].
EDS type IV should therefore be considered after any
ischemic stroke in young subject [5,23]. In addition,
intracranial haemorrhages are found in 4% of cases, half
of which are caused by the rupture of a previously-identi-
fied intracranial aneurysm [20]. This prevalence appears
higher than in the general population, where the fre-
quency of unruptured aneurysms is estimated between
0.5 and 1% [19]. Early diagnosis of brain haemorrhage in
patients with EDS type IV is important, as it has significant
implications for the care of patients and their relatives. In
patients with confirmed diagnosis of vascular EDS, non-
invasive techniques (echo-Doppler, angioscan, angio-
MRI) are absolutely imperative for diagnosing arterial dis-
sections or aneurysms [24]. Arteriograms are associated
with a high rate of complications at the point of puncture
and/or tear of the arterial wall and are thus contraindi-
cated [25]. The benefit/risk ratio of any invasive diagnos-
tic procedure should be carefully assessed and arteriogram
reserved only for cases where arterial embolisation is
planned [24]. If thrombosis occurs after carotid or verte-
bral dissection, anticoagulation may be required but
should be carried out with care. Surgical treatment of
brain aneurysms has a high morbidity mortality rate
owing to the brittle nature of the tissue in these patients.
Endovascular radiology treatments also have a high post-
treatment morbidity and mortality [22,24].
Angio-MRI (coronal section) of the supra-aortic vessels after  injection of 20 cc of gadolinium in a woman aged 24 with EDS  type IV, revealing a dissecting haematoma of the left internal  carotid (black arrow), a bilateral dissection of the vertebral  arteries in their V1 and V2 segments (white arrows) and a  dissection of the middle and distal third of the right subcla- vian artery (head of arrow) Figure 2
Angio-MRI (coronal section) of the supra-aortic vessels after 
injection of 20 cc of gadolinium in a woman aged 24 with EDS 
type IV, revealing a dissecting haematoma of the left internal 
carotid (black arrow), a bilateral dissection of the vertebral 
arteries in their V1 and V2 segments (white arrows) and a 
dissection of the middle and distal third of the right subcla-
vian artery (head of arrow).
Extensive bruising of the legs in a child affected with Ehlers- Danlos syndrome type IV Figure 1
Extensive bruising of the legs in a child affected with Ehlers-
Danlos syndrome type IV.Orphanet Journal of Rare Diseases 2007, 2:32 http://www.OJRD.com/content/2/1/32
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The low instance of cerebrovascular complications does
not work in favour of systematic scanning for brain aneu-
rysms in asymptomatic patients suffering from EDS type
IV, in whom the risks linked to surgery often contraindi-
cate surgery before the appearance of symptoms [19].
There is some controversy about the usefulness of serial
vascular check-up. Some experts advise against them
because of the anxiety that the discovery of aneurysmal
lesions (for which a treatment decision would rarely be
taken) may provoke in the patients. Many authors,
though, recommend carrying out an annual or biennial
check-up including an ultrasound scan of the supra-aortic
vessels and the arterial axes of the lower limbs, and a tho-
racic-abdominal scan with careful, low pressure injection
[24]. The discovery of a previously unknown large or rap-
idly-expanding aneurysm requires close monitoring. For a
fortuitously-discovered vascular lesion which threatens
the vital prognosis, the planned surgery is thus appropri-
ate outside of an emergency context, even though post-
operative treatments are often complicated by haemor-
rhages or tears of the anastomoses [8].
2) Digestive complications
Most perforations occur in the sigmoid colon [26] but the
small intestine can occasionally be affected (Germain DP,
unpublished data). Spontaneous ruptures of the spleen
and the liver have also been described [27]. There is a high
risk (50%) of multiple colonic perforations and leakage
from the anastomosis in case of simple segmental resec-
tion with immediate re-establishment of continuity
[12,28]. The treatment of choice is therefore partial colec-
tomy with colostomy, possibly followed by secondary re-
establishment of continuity (Figure 4). Alternatively, total
colectomy with ileostomy and closure of the rectal stump
or ileo-rectal anastomosis may be proposed despite the
young age of patients, because of the risk of recurrent
colonic perforations and the scarcity of perforations of the
small intestine [16]. There is a significant risk of leakage
on the anastomosis.
Mortality due to digestive perforations in patients suffer-
ing from vascular EDS is relatively low, estimated at 2%
[1] and, therefore, lower than some descriptions from iso-
lated clinical cases may indicate [29].
3) Obstetrical complications
Pregnancy can increase the likelihood of a uterine or vas-
cular rupture in women suffering from EDS type IV (par-
ticularly during the last three months) [30]. Maternal
mortality stands at around 12% [1,5,31]. The highest is
the risk during labour, delivery and immediate post-par-
tum period. Uterine haemorrhages occur frequently dur-
ing the post-partum period and are sometimes only
treatable by hysterectomy. The value of a caesarean carried
out before the onset of labour (in order to minimise the
risks related to contractions and take better control of hae-
mostasis) [32] has not yet been the subject of a controlled
Surgical laparotomy scar following sigmoid colon perforation  in a young patient presenting with vascular Ehlers-Danlos  syndrome Figure 4
Surgical laparotomy scar following sigmoid colon perforation 
in a young patient presenting with vascular Ehlers-Danlos 
syndrome.
Cerebral angio-MRI after injection of 20 cc of gadolinium in a  woman aged 24 with EDS type IV displaying a dissecting hae- matoma of the left internal carotid Figure 3
Cerebral angio-MRI after injection of 20 cc of gadolinium in a 
woman aged 24 with EDS type IV displaying a dissecting hae-
matoma of the left internal carotid.Orphanet Journal of Rare Diseases 2007, 2:32 http://www.OJRD.com/content/2/1/32
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study [24]. The prophylactic use of desmopressin to con-
trol primary haemostasis has been proposed [33].
4) Pleuropulmonary complications
Pneumothoraces, haemoptysis [34] and haemorrhagic
cavitary lesions [35] of the pulmonary parenchyma have
occurred in several patients suffering from EDS type IV
[6].
5) Mitral valve prolapse
An increased frequency of mitral valve prolapse (MVP)
has been reported in patients with EDS type IV [36]. How-
ever, it should be noted that this is the case in many inher-
ited disorders of connective tissue and that the exact
prevalence of MVP in the general population is unknown
[7].
Aetiology
Genetics
Mode of transmission
Vascular EDS is caused by heterozygote mutations of the
COL3A1 gene and is transmitted as an autosomal domi-
nant trait [1,5,7,37].
Gene location
Type III collagen is coded by an unique gene, COL3A1,
whose locus is situated on the long arm of chromosome
2, in position 2q24.3-q31 [38]. Linkage analyses have
demonstrated that vascular EDS co-segregates with poly-
morphic markers in this locus [39]. There is no genetic
heterogeneity and the polymorphic markers in the
COL3A1 locus can occasionally allow the allele associated
with the disease to be identified in families and can prove
useful for indirect molecular diagnosis.
Physiopathology
Collagens are a family of proteins that contribute to the
organisation of the extracellular matrix, comprising at
least 19 proteins coded by at least 35 non-allelic genes dis-
persed in the genome [40]. EDS type IV is caused by a def-
icit of type III collagen, which belongs to the fibrillar
collagens. All fibrillar collagens are homo- or heterot-
rimerics formed by the linking of three monomers or α
chains. Type III collagen is a homotrimeric formed by the
linking of three α1(III) chains, with the central part of the
molecule adopting a triple-helix structure. The amino acid
sequence of the triple helix is characterised by repeated
glycine-X-Y sequences, where X and Y are often the amino
acids proline and hydroxyproline respectively. In order to
ensure correct linking of α monomers, there should be no
interruption in the repetition of the glycine-X-Y triplets
and the length of the triple helix should remain similar for
each α chain [5].
Type III collagen is a constituent of arterial walls. Its quan-
titative or qualitative deficit in EDS type IV accounts for
the propensity of arterial tears or dissections which char-
acterise this illness. The walls of the digestive tract are also
rich in type III collagen, which explains why digestive per-
forations are another frequent complication of EDS type
IV [41,42].
Diagnosis
Clinical criteria (Table 2)
Diagnosis of EDS type IV is mainly clinical and is easier
when the patient is acrogeric, has a positive family history
or has displayed a first instance of arterial or digestive
complication.
Laboratory diagnosis
1) Biochemical diagnosis
The study of the secretion of collagen III by skin fibrob-
lasts may demonstrate a quantitative or qualitative deficit
with abnormal migration of the proα1(III) chains to elec-
trophoresis of proteins on polyacrylamide denaturant gel
(Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis,
SDS-PAGE) (Figure 5) [37].
2) Molecular biology
The publication of the complementary DNA (cDNA)
sequence of the COL3A1 gene has paved the way towards
understanding of the molecular basis of EDS type IV [43-
45]. Direct molecular analysis, which is difficult because
of the large size of the gene and the major allelic heteroge-
Table 2: Vascular Ehlers-Danlos syndrome: Villefranche diagnostic criteria (adapted from [3]
Major diagnosis criteria Arterial, digestive or uterine fragility or rupture
Thin, translucent skin
Extensive bruising
Characteristic facial appearance
Minor diagnosis criteria Positive family history, sudden death in a close relative
Acrogeria
Hypermobility of small joints
Tendon and muscle rupture
Talipes equinovarus (clubfoot)
Early onset varicose veins
Spontaneous pneumothorax or haemothoraxOrphanet Journal of Rare Diseases 2007, 2:32 http://www.OJRD.com/content/2/1/32
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neity, allows the mutation of the COL3A1 gene to be char-
acterised exactly (Figure 6). EDS type IV can be caused by
missense point mutations affecting the glycine residues of
the triple helix [46], splicing mutations with exon skip-
ping [47], small or large deletions [44] or haploinsuff-
iency [48]. Each mutation is particular to a given family
[5,49].
3) Histology
Optical microscopy
The observation of a skin biopsy via optical microscopy
does not usually contribute a great deal but can occasion-
ally reveal a thinned dermis, within which the groups of
collagen appear sparse and/or irregular [5].
Electron microscopy
Ultrastructure study can sometimes reveal images of dila-
tion of the granular endoplasmic reticulum of the skin
fibroblasts, irregularities in the diameter of collagen fibres
and an unidentified fibrino-granular substance within the
extracellular matrix. Given the high number of false nega-
tives, the absence of these images should not exclude the
diagnosis EDS type IV [5].
4) Haemostasis
Haemostasis tests are normal with the possible exception
of an increased bleeding time in some patients. The ten-
dency toward haemorrhages in EDS type IV therefore
appears to be due to fragility of the tissue and the capillar-
ies, rather than a thrombocytic or plasmatic defect [50].
Differential diagnosis
In childhood, coagulation disorders and Silverman's syn-
drome are the most often-cited differential diagnoses,
owing to the propensity for haematomas and ecchymoses
in EDS type IV. In adulthood, the other Ehlers-Danlos
syndromes, as well as Marfan syndrome (OMIM
#154700) and Loeys-Dietz syndrome (OMIM #609192)
caused by mutations in the genes TGFR1  (OMIM
#190181) or TGFR2 (OMIM #190182) [51,52], and arte-
rial tortuosity syndrome (OMIM 208050) caused by a def-
icit in GLUT10 [53] can sometimes pose a problem.
Similarly, when no mutation of the COL3A1  gene has
been identified, the possible existence of yet unidentified
hereditary disorders of connective tissue causing arterial
aneurysms or dissections, and therefore mimicking EDS
type IV, should be considered. In contrast, we recently
reported a syndrome of joint hyperlaxity, easy bruising,
pelvic organs prolapses, premature rupture of the mem-
branes and rectal bleeding associated with a non-glycine
sequence variant of the COL3A1  gene (P435T) [54].
Whether non-glycine mutations of the COL3A1 gene may
be responsible for a phenotype different from EDS type IV
warrants further studies [54].
Sodium dodecyl sulfate-PolyAcrylamide Gel Electrophoresis  (SDS-PAGE) analysis of collagens secretion in a patient  affected with vascular EDS and a control Figure 5
Sodium dodecyl sulfate-PolyAcrylamide Gel Electrophoresis 
(SDS-PAGE) analysis of collagens secretion in a patient 
affected with vascular EDS and a control. The band corre-
sponding to type III collagen is indicated by α1(III). Columns 
1 and 3 correspond to the supernatant culture medium of 
the cutaneous fibroblasts. Colums 2 and 4 correspond to cell 
extracts. Secretion of type III collagen in the medium is 
reduced in the patient (column 1) as compared to the con-
trol (column 3). Conversely, there is intracellular retention 
of abnormal collagen in the cell extracts of the patient (col-
umn 2) as compared to the control. In addition, the mutant 
collagen III has a higher molecular weight due to additional 
post-translational modification α1(III)M.Orphanet Journal of Rare Diseases 2007, 2:32 http://www.OJRD.com/content/2/1/32
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Management including treatment
In the absence of specific treatment for EDS type IV, med-
ical intervention should be focused on symptomatic treat-
ment, prophylactic measures and genetic counselling.
Patients should be advised to carry with them a letter or a
card (such as the European Ehlers-Danlos syndrome pass-
port) indicating the nature of their illness, the vascular or
digestive complications to which they are at risk, their
blood group and the contact details of a medical practi-
tioner [5]. Intense physical activity, scuba diving and vio-
lent sports are inadvisable. Various medications such as
acetylsalicylic acid, clopidogrel and/or antivitamin K
drugs interfere with platelets functions or coagulation and
should therefore be avoided.
Arterial, digestive or uterine complications require imme-
diate hospitalisation, observation in an intensive care unit
and sometimes surgery [24]. Arteriograms and endoscop-
ies are contraindicated in principle. Conservative
approach is usually recommended when caring for a vas-
cular complication in a patient suffering from EDS type IV
[24]. When the vital prognosis is not at stake, therapeutic
abstention with close monitoring is indeed preferable to
unjustified surgery [24].
Surgery may, however, be required urgently to treat poten-
tially fatal complications such as uncontrolled haemor-
rhage or a very large or rapidly-expanding aneurysm
[8,24]. To optimise the chances of success, the surgeon
should be informed of the diagnosis before beginning sur-
gery. Surgical precautions include delicate and atraumatic
handling of tissues. The surgeon must choose the least
complex and most direct repair technique possible [16].
The arterial ligature is an excellent choice when it does not
compromise the bloody supply of an organ [24]. Simple
arterial repairs have been successfully carried out in some
cases [8]. Serious arterial complications require arterial
reconstruction with prosthetic material. Anastomoses
should not be carried out with tension but strengthened
by Teflon pledgets. Despite these precautions, a number of
patients develop post-operative haemorrhagic complica-
tions, as well as problems relating to anastomosis of the
prosthetic graft [8]. At present, the information on the use
of stents to treat vascular complications of EDS type IV is
insufficient. The risk of arterial rupture distantly from the
point of puncture is high. In all cases, it is imperative the
post-operative monitoring to be prolonged and the post-
operative checks by non-invasive imaging techniques
(scanners) repeated [24]. It is essential that patients suffer-
Detection of a heterozygote missense mutation (G514V) in the COL3A1 gene in a 47-year old female patient affected with  Ehlers-Danlos syndrome type IV Figure 6
Detection of a heterozygote missense mutation (G514V) in the COL3A1 gene in a 47-year old female patient affected with 
Ehlers-Danlos syndrome type IV. A G to A substitution was found at nucleotide position 2042 starting from the initiation 
codon (ATG) of the COL3A1 gene. This nucleotide substitution alters the codon (GGT) for glycine to the codon (GTT) for 
valine at position 514 of the α-chain of collagen type III protein. Two electrophoregrams of the same patient are shown. (Fig-
ure courtesy of Prof. X. Jeunemaitre)Orphanet Journal of Rare Diseases 2007, 2:32 http://www.OJRD.com/content/2/1/32
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ing from EDS type IV are not offered surgical procedures
that are unessential, such as stripping of varicose veins
[4,55].
Pregnant women with vascular EDS should be considered
at risk and receive special care [32,56,57].
Genetic counselling
Once the diagnosis has been confirmed, the opinion of a
geneticist should be sought and family screening carried
out. EDS type IV is a monogenic disorder, of autosomal
dominant transmission [5]. Patients affected have a 50%
risk of transmitting the disease to each of their children.
The rate of de novo mutations is high and sporadic cases
account for about half of all cases of EDS type IV. The
hypothesis of recessive autosomal transmission of EDS
type, still proposed in the eleventh edition of the heredi-
tary monogenic disorders catalogue (OMIM), should be
dismissed [5,7].
Prenatal diagnosis
Molecular prenatal diagnosis can be considered for fami-
lies where the mutation is known. Choriocentesis or
amniocentesis entail, in theory, risks linked to the obstet-
ric procedure in couples where the woman suffers from
EDS type IV. Artificial insemination with donor sperm
(when the patient is male) and adoption are other options
to discuss with the couple during genetic counselling.
Research prospects
The value of long-term beta blocker treatment (celiprolol)
to prevent vascular complications in EDS type IV [58] is
currently the subject of a controlled clinical trial (Clinical-
Trials.gov Identifier: NCT00190411). However, its statisti-
cal analysis should focus on verifying the definite absence
of methodological bias which the inclusion of patients
with erroneous diagnosis of EDS type IV would constitute.
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